Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that its Board's Compensation Committee has approved inducement awards for twelve new employees. The awards consist of non-statutory options to purchase 131,700 ordinary shares under the company's 2021 Inducement Plan. These options come with a ten-year term and follow a four-year vesting schedule, with 25% vesting on the first anniversary of each employee's start date and subsequent 25% portions vesting on the second, third, and fourth anniversaries. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato che il Comitato per la Retribuzione del suo Consiglio ha approvato premi di indennità per dodici nuovi dipendenti. I premi consistono in opzioni non statutarie per acquistare 131.700 azioni ordinarie secondo il Piano di Indennità 2021 dell'azienda. Queste opzioni hanno un periodo di validità di dieci anni e seguono un piano di maturazione di quattro anni, con il 25% che matura al primo anniversario della data di inizio di ciascun dipendente e porzioni successive del 25% che maturano nei secondi, terzi e quarti anniversari. Le concessioni sono state effettuate in conformità con la Regola di Listing di Nasdaq 5635(c)(4) come materiale di indennità per l'accettazione dell'impiego.
Avadel Pharmaceuticals (Nasdaq: AVDL) anunció que el Comité de Compensación de su Junta ha aprobado premios de inducción para doce nuevos empleados. Los premios consisten en opciones no estatutarias para comprar 131,700 acciones ordinarias bajo el Plan de Inducción 2021 de la empresa. Estas opciones tienen un plazo de diez años y siguen un calendario de adquisición de cuatro años, con el 25% que se adquiere en el primer aniversario de la fecha de inicio de cada empleado y porciones del 25% que se adquieren en los segundos, terceros y cuartos aniversarios. Las concesiones se realizaron de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) como material de inducción para la aceptación del empleo.
아바델 제약(나스닥: AVDL)은 이사회 보상위원회가 열두 명의 신입 사원을 위한 유인 보상을 승인했다고 발표했습니다. 이 보상은 회사의 2021년 유인 계획에 따라 131,700주의 보통주를 매수할 수 있는 비적격 옵션으로 구성됩니다. 이 옵션은 10년 동안 유효하며 4년의 분할 일정에 따릅니다. 각 직원의 시작일 첫 번째 기념일에 25%가 분할되고, 두 번째, 세 번째 및 네 번째 기념일에 각각 25%씩이 추가로 분할됩니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 고용 수락을 위한 유인 자료로 제공되었습니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé que le Comité de Rémunération de son Conseil a approuvé des attributions incitatives pour douze nouveaux employés. Ces attributions consistent en des options non statutaires pour acheter 131 700 actions ordinaires dans le cadre du Plan d'Induction 2021 de l'entreprise. Ces options ont une durée de dix ans et suivent un calendrier d'acquisition de quatre ans, avec 25% devenant acquis lors du premier anniversaire de la date de début de chaque employé et des portions supplémentaires de 25% devenant acquises lors des deuxième, troisième et quatrième anniversaires. Les attributions ont été faites conformément à la règle 5635(c)(4) de Nasdaq en tant que matériel incitatif pour l'acceptation de l'emploi.
Avadel Pharmaceuticals (Nasdaq: AVDL) gab bekannt, dass der Vergütungsausschuss des Vorstands Bindungsprämien für zwölf neue Mitarbeiter genehmigt hat. Die Prämien bestehen aus nicht-statutären Optionen zum Erwerb von 131.700 Stammaktien gemäß dem Induktionsplan 2021 des Unternehmens. Diese Optionen haben eine Laufzeit von zehn Jahren und folgen einem vierjährigen Vesting-Plan, wobei 25% am ersten Jahrestag des Eintritts eines jeden Mitarbeiters und die verbleibenden 25% am zweiten, dritten und vierten Jahrestag fällig werden. Die Gewährung erfolgte gemäß der Nasdaq-Notierungsregel 5635(c)(4) als Bindungsmaterial für die Annahme der Anstellung.
- Addition of 12 new employees indicates company expansion
- Structured vesting schedule helps retain talent over 4 years
- Potential dilution of existing shareholders due to 131,700 new share options
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688
FAQ
How many shares were granted in AVDL's January 2024 inducement awards?
What is the vesting schedule for AVDL's 2024 inducement awards?
How long is the term of AVDL's January 2024 inducement options?
Under which plan were AVDL's January 2024 inducement awards granted?
What Nasdaq rule governs AVDL's January 2024 inducement awards?
